Knowledge HQ

The authors developed a feeder-free, xeno-free protocol for NK cell expansion using NK Cloudz microspheres in G-Rex6M vessels with human platelet lysate. The method achieved ~387-fold expansion in 10 days with high purity and cytotoxicity, offering a scalable alternative to feeder cell-based methods.

The authors developed BOXR1030, a GPC3-targeted CAR T cell co-expressing GOT2 to enhance metabolism. T cells were expanded in G-Rex 10 or 100 units. BOXR1030 demonstrated superior in vivo antitumor activity, reduced exhaustion, and better persistence in solid tumor xenograft models compared to control CARs.

This study demonstrates that genome editing with TALEN or CRISPR can restore SAP expression and function in T cells from XLP patients. PBMC stimulation and culture were performed in G-Rex 24 plates. Edited cells showed physiological SAP levels and restored immune functions, suggesting a viable therapeutic approach.

Due to supply chain shortages, the authors validated G-Rex vessels as an alternative to Wave bioreactors for CAR T expansion. G-Rex 1L vessels produced 2-4 billion T cells with >90% viability and comparable phenotype/function, using significantly less media and labor than the Wave system.

This study optimized the expansion of cytokine-induced killer (CIK) and blinatumomab-expanded T cells (BET) in G-Rex devices. G-Rex allowed for expansion to >30 million cells/cm2 in 10-11 days with minimal manipulation, significantly faster than T-flasks, while maintaining cell phenotype and function.

The authors describe a robust method for expanding Vd1 gamma-delta T cells using OKT-3 and IL-15. Culture in 6-well G-Rex vessels supported >1000-fold expansion in some donors. The expanded Vd1 cells were efficiently transduced with CARs and demonstrated potent antigen-specific cytotoxicity.

This paper presents a scalable platform for allogeneic T cell manufacturing using stirred-tank bioreactors (STR) with perfusion. It compares STR performance to G-Rex, noting that while G-Rex achieved 28-fold expansion, the perfused STR achieved 167-fold expansion, demonstrating superior scalability.

This article evaluates TAK-186, a protease-activated T cell engager. Human T cells used for in vivo efficacy studies were expanded using G-Rex 100. TAK-186 demonstrated regression of EGFR+ solid tumors in mice, validating the conditional activation design in a tumor microenvironment.

The study identified IL-15 + IL-7 as the optimal cytokine cocktail for expanding SARS-CoV-2-specific T cells (CSTs). Results were translated to a GMP-applicable format using G-Rex 10, which showed improved expansion and specificity, particularly for CD8+ T cells, compared to IL-4 + IL-7.

This protocol details the manufacturing of CAR Tregs for non-human primates. G-Rex 6-well plates were used to expand K562 artificial antigen-presenting cells (aAPCs), which were subsequently used to stimulate Tregs. The method yields highly suppressive CAR Tregs for pre-clinical studies.

This study evaluates the impact of cryopreservation on CAR T cell production. Cells were expanded in G-Rex100, which facilitated simple media top-ups. The study found that cryopreserved PBMCs and CAR T products yielded comparable expansion and clinical responses to fresh materials.

This poster presents a G-Rex-based method for expanding lentiviral transduced HSPCs to determine vector copy number (VCN). Compared to standard plates, G-Rex cultures showed higher expansion rates, high viability, and similar lineage phenotypes, providing a less laborious and cost-effective method for QC testing.